Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemoradiation for Muscle-Invasive Bladder Cancer
NCT05975307Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in muscle-invasive bladder cancer (MIBC), sponsored by Sun Yat-sen University. Started Dec 2023; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT05975307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975307.